The estimated Net Worth of James Edeerfield Capital Lp... is at least 6.3 百万$ dollars as of 28 April 2006. James Lp owns over 69,200 units of Dynavax Technologies stock worth over 6,304,049$ and over the last 19 years James sold DVAX stock worth over 0$.
James has made over 6 trades of the Dynavax Technologies stock since 2006, according to the Form 4 filled with the SEC. Most recently James bought 69,200 units of DVAX stock worth 384,752$ on 28 April 2006.
The largest trade James's ever made was buying 142,085 units of Dynavax Technologies stock on 20 April 2006 worth over 781,468$. On average, James trades about 86,630 units every 8 days since 2006. As of 28 April 2006 James still owns at least 577,823 units of Dynavax Technologies stock.
You can see the complete history of James Lp stock trades at the bottom of the page.
Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. Hack、Partners L P/Ilbiotechnolog...、James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: